205 related articles for article (PubMed ID: 21452059)
1. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
[TBL] [Abstract][Full Text] [Related]
2. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.
Kamiyama H; Takano S; Tsuboi K; Matsumura A
J Cancer Res Clin Oncol; 2005 Apr; 131(4):205-13. PubMed ID: 15583935
[TBL] [Abstract][Full Text] [Related]
4. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
6. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
7. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.
Greenberger LM; Horak ID; Filpula D; Sapra P; Westergaard M; Frydenlund HF; Albaek C; Schrøder H; Ørum H
Mol Cancer Ther; 2008 Nov; 7(11):3598-608. PubMed ID: 18974394
[TBL] [Abstract][Full Text] [Related]
8. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
9. Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.
Li G; Shan C; Liu L; Zhou T; Zhou J; Hu X; Chen Y; Cui H; Gao N
PLoS One; 2015; 10(2):e0117440. PubMed ID: 25659153
[TBL] [Abstract][Full Text] [Related]
10. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
Jeong W; Park SR; Rapisarda A; Fer N; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
Invest New Drugs; 2014 Apr; 32(2):340-6. PubMed ID: 24242862
[TBL] [Abstract][Full Text] [Related]
11. Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1α via the mTOR/p70S6K/4E-BP1 and MAPK pathways.
Mi C; Ma J; Wang KS; Zuo HX; Wang Z; Li MY; Piao LX; Xu GH; Li X; Quan ZS; Jin X
J Ethnopharmacol; 2017 May; 203():27-38. PubMed ID: 28341244
[TBL] [Abstract][Full Text] [Related]
12. Role of vincristine in the inhibition of angiogenesis in glioblastoma.
Park KJ; Yu MO; Park DH; Park JY; Chung YG; Kang SH
Neurol Res; 2016 Oct; 38(10):871-9. PubMed ID: 27472259
[TBL] [Abstract][Full Text] [Related]
13. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
[TBL] [Abstract][Full Text] [Related]
14. Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
Takano S; Kamiyama H; Mashiko R; Osuka S; Ishikawa E; Matsumura A
J Neurooncol; 2010 Sep; 99(2):177-85. PubMed ID: 20066473
[TBL] [Abstract][Full Text] [Related]
15. Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.
Sapra P; Kraft P; Mehlig M; Malaby J; Zhao H; Greenberger LM; Horak ID
Haematologica; 2009 Oct; 94(10):1456-9. PubMed ID: 19794091
[TBL] [Abstract][Full Text] [Related]
16. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.
Chang CC; Lin MT; Lin BR; Jeng YM; Chen ST; Chu CY; Chen RJ; Chang KJ; Yang PC; Kuo ML
J Natl Cancer Inst; 2006 Jul; 98(14):984-95. PubMed ID: 16849681
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.
Pourgholami MH; Cai ZY; Badar S; Wangoo K; Poruchynsky MS; Morris DL
BMC Cancer; 2010 Apr; 10():143. PubMed ID: 20398289
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway.
Cai WB; Zhang Y; Cheng R; Wang Z; Fang SH; Xu ZM; Yang X; Yang ZH; Ma JX; Shao CK; Gao GQ
PLoS One; 2012; 7(12):e53152. PubMed ID: 23300882
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1α.
Nepal M; Choi HJ; Choi BY; Kim SL; Ryu JH; Kim DH; Lee YH; Soh Y
Eur J Pharmacol; 2012 Sep; 691(1-3):28-37. PubMed ID: 22760073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
